Alcon ALC shares ended the last trading session 6% higher at $96.80. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares ...

Eye care giant Alcon appears to have gained the upper hand in the ongoing power struggle with Aurion Biotech by securing a majority stake in the clinical-stage company and replacing its CEO.

Eye care company Alcon Inc., which has a major presence in North Texas, plans to buy Lensar Inc. in a deal valued up to $430 million. Orlando-based Lensar (Nasdaq: LNSR) is a laser cataract ...

Alcon acquired a majority interest in Aurion Biotech, a clinical-stage company developing advanced cell therapies to treat eye diseases. Terms of the deal weren't disclosed. Aurion will operate as ...

Swiss eyecare firm Alcon said on Monday it has agreed to a deal worth a potential $430 million with US counterpart Lensar, which offers advanced laser solutions for cataract treatments. In a joint ...